EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DavidCG who wrote (1320)	10/24/1998 7:25:00 PM
From: ACC	Read Replies (1) of 2135

DavidCG, Remember their history - as far back as 1996, they published in Nature Medicine (Nat Med 1996 Jun;2(6):689-92) their findings of an astounding response to angiostatin treatment in mice transplanted with "three human and three murine primary carcinomas." granted prostate ca is a slower growing cancer, and a response in such a tumor is indeed encouraging and continues to support dr. folkman's basic philosophy about anti-angiogenesis, but i don't expect any ground-breaking info monday. now if we could only translate that into something concrete for the oncology patients and perhaps (selfishly) increased earnings for enmd. still, i am looking forward to their presentation. if it's the usual conference format it will be a short (10-15 minute) talk with brief q&a to follow. wish i could predict which way enmd will go monday, but i'm not overly optimistic for a large jump - just my opinion, no data. long from the start, ACC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next